These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30234973)

  • 1. Bioengineered Norovirus S
    Xia M; Huang P; Sun C; Han L; Vago FS; Li K; Zhong W; Jiang W; Klassen JS; Jiang X; Tan M
    ACS Nano; 2018 Nov; 12(11):10665-10682. PubMed ID: 30234973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Norovirus Capsid Protein-Derived Nanoparticles and Polymers as Versatile Platforms for Antigen Presentation and Vaccine Development.
    Tan M; Jiang X
    Pharmaceutics; 2019 Sep; 11(9):. PubMed ID: 31547456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rotavirus NSP4 protein on the immune response and protection of the S
    Liu C; Huang P; Zhao D; Xia M; Zhong W; Jiang X; Tan M
    Vaccine; 2021 Jan; 39(2):263-271. PubMed ID: 33309483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pseudovirus Nanoparticle-Based Trivalent Rotavirus Vaccine Candidate Elicits High and Cross P Type Immune Response.
    Xia M; Huang P; Tan M
    Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response and protective efficacy of the S particle presented rotavirus VP8* vaccine in mice.
    Xia M; Huang P; Jiang X; Tan M
    Vaccine; 2019 Jul; 37(30):4103-4110. PubMed ID: 31201052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Viral Protein 4-Based Trivalent Nanoparticle Vaccine Elicited High and Broad Immune Responses and Protective Immunity against the Predominant Rotaviruses.
    Xia M; Huang P; Vago F; Kawagishi T; Ding S; Greenberg HB; Jiang W; Tan M
    ACS Nano; 2024 Feb; 18(8):6673-6689. PubMed ID: 38353701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Nanoparticle-Based Trivalent Vaccine Targeting the Glycan Binding VP8* Domains of Rotaviruses.
    Xia M; Huang P; Jiang X; Tan M
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33419150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Norovirus P particle, a novel platform for vaccine development and antibody production.
    Tan M; Huang P; Xia M; Fang PA; Zhong W; McNeal M; Wei C; Jiang W; Jiang X
    J Virol; 2011 Jan; 85(2):753-64. PubMed ID: 21068235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus.
    Tan M; Jiang X
    Nanomedicine (Lond); 2012 Jun; 7(6):889-97. PubMed ID: 22734641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Branched-linear and agglomerate protein polymers as vaccine platforms.
    Wang L; Xia M; Huang P; Fang H; Cao D; Meng XJ; McNeal M; Jiang X; Tan M
    Biomaterials; 2014 Sep; 35(29):8427-38. PubMed ID: 24985736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus.
    Xia M; Wei C; Wang L; Cao D; Meng XJ; Jiang X; Tan M
    Sci Rep; 2016 May; 6():25735. PubMed ID: 27194006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dual chicken IgY against rotavirus and norovirus.
    Dai YC; Zhang XF; Tan M; Huang P; Lei W; Fang H; Zhong W; Jiang X
    Antiviral Res; 2013 Mar; 97(3):293-300. PubMed ID: 23267830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioengineered pseudovirus nanoparticles displaying the HA1 antigens of influenza viruses for enhanced immunogenicity.
    Xia M; Hoq MR; Huang P; Jiang W; Jiang X; Tan M
    Nano Res; 2022; 15(5):4181-4190. PubMed ID: 35106126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyvalent complexes for vaccine development.
    Wang L; Huang P; Fang H; Xia M; Zhong W; McNeal MM; Jiang X; Tan M
    Biomaterials; 2013 Jun; 34(18):4480-92. PubMed ID: 23498893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological response to recombinant VP8* subunit protein of bovine roravirus in pregnant cattle.
    Lee J; Babiuk LA; Harland R; Gibbons E; Elazhary Y; Yoo D
    J Gen Virol; 1995 Oct; 76 ( Pt 10)():2477-83. PubMed ID: 7595351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a bivalent recombinant vaccine candidate targeting norovirus and rotavirus: Antibodies to rotavirus NSP4 exert antidiarrheal effects without virus neutralization.
    Cao H; Wu J; Luan N; Wang Y; Lin K; Liu C
    J Med Virol; 2022 Aug; 94(8):3847-3856. PubMed ID: 35474320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The αTSR Domain of
    Xia M; Vago F; Han L; Huang P; Nguyen L; Boons GJ; Klassen JS; Jiang W; Tan M
    Int J Nanomedicine; 2023; 18():3087-3107. PubMed ID: 37312932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and protective efficacy in an animal model of a novel truncated rotavirus VP8 subunit parenteral vaccine candidate.
    Xue M; Yu L; Che Y; Lin H; Zeng Y; Fang M; Li T; Ge S; Xia N
    Vaccine; 2015 May; 33(22):2606-13. PubMed ID: 25882173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and testing of a highly conserved human rotavirus VP8* immunogenic peptide with potential for vaccine development.
    Mohanty E; Dehury B; Satapathy AK; Dwibedi B
    J Biotechnol; 2018 Sep; 281():48-60. PubMed ID: 29886031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homotypic protection against rotavirus-induced diarrhea in infant mice breast-fed by dams immunized with the recombinant VP8* subunit of the VP4 capsid protein.
    Gil MT; de Souza CO; Asensi M; Buesa J
    Viral Immunol; 2000; 13(2):187-200. PubMed ID: 10892999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.